semaglutide injection patent expiry in India 2026 | Mr GOKUL K S posted on the topic semaglutide injection patent expiry Zydus

NICE guidance for the use of GLP-1 receptor agonists in type 2 diabetes (NG28) and for weight management (the current NICE Technology Appraisal for semaglutide 2

Retatrutide is the first and only triple receptor agonist to reach Phase 3 clinical trials

Several studies indicate that a sustained weight loss of at least 10% of initial body weight improves several complications associated with obesity, including the prevention and control of type 2 diabetes, hypertension, fatty liver disease and sleep apnea

Get weekly health news Health Canada says Svemia is for the once-weekly treatment of people 12 and over, as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management